The Standards for TB care in India explains the TB treatment in India that should be provided for all people with TB. It was published in 2014 and explains the TB treatment that should be provided for all patients with TB. This includes people in special groups, such as those with TB and HIV co-infection.
Later the Technical & Operational Guidelines for Tuberculosis Control in India 2016 was produced. This document does not replace the Standards for TB Care in India. It does update it as well as expand it. In particular it makes it clear that the Standards for TB Care in India applies to all patients including those in the private sector.
By the time that a person has been diagnosed as having TB disease they should know whether they have pulmonary or extra pulmonary TB. Most people will have pulmonary TB. Pulmonary TB is TB in the lungs. Extra pulmonary TB is TB involving any organ apart from the lungs.
It is also very important that a patient, or someone close to them, is able to say whether they have ever had any TB treatment before. If you have had TB treatment before, you will probably need to take different TB drugs to those people who have never had TB treatment before.
It is also important to know if there is any possibility that you have drug resistant TB. There is more about drug resistant TB in India.
Patient will be in one of three groups based on their history of TB treatment. These groups are:
a) New TB patients – these are TB patients who have never had treatment for TB or they have taken anti TB drugs for less than one month.
b) Previously treated patients – these are patients who have received one month or more of anti TB drugs in the past.
Recurrent TB patients are patients who have previously been considered as successfully treated (cured/treatment completed) and they have subsequently been micro biologically confirmed as still having TB.
Treatment after failure patients are those who have previously been treated for TB and their treatment failed at the end of their most recent course of treatment.
Treatment after lost to follow-up is a TB patient who has previously received TB treatment for a month or more and they were declared lost to follow up in their most recent course of treatment. They have also subsequently been found to be a microbiologically confirmed TB case.
Other previously treated patients are patients who have previously been treated but whose outcome after their most recent course of treatment is unknown or undocumented.
c) Transferred in – is a TB patient who is received for treatment in a TB unit, after being registered for treatment in another TB unit.
A micro biologically confirmed TB case refers to a patient who is presumed to have TB and who has a biological specimen positive for acid fast bacilli. It is also a patient positive for TB through a quality assured Rapid Diagnostic Molecular test, such as CB-NAAT.
All new TB patients in India should receive an internationally accepted first line treatment regimen (a regimen is the prescribed course of treatment, in this case the TB drugs) for new patients.
The initial intensive phase should consist of eight weeks of the drugs Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) and Ethambutol (E). The continuation phase should consist of the three drugs Isoniazid, Rifampicin and Ethambutol given for another sixteen weeks. This is alternatively written as 2HREZ/4 – 6HRE. There will be no need for any extension of the continuation phase.
The drug dosages should be given according to the body weight of the patient. There will be four weight band categories.
All patients should receive their daily TB drugs under direct observation (DOTS). Under DOTS (Directly Observed Therapy Short Term) the patient has to take the TB medication in front of a DOTS agent. The DOTS agent is usually a volunteer from the patient’s community, and may be a family member. DOTS does not say which drugs should be taken. DOTS applies when any TB drugs are taken with the patient being observed by a DOTS volunteer.
A fixed dose combination (FDC) is when two or more drugs are combined together in a single pill or tablet.
Fixed dose combinations are helpful as they simplify getting TB drugs and the delivery of DOTS. They may also increase adherence. Individually worked out drug dosing should be only used for patients with toxicities or contraindications to one or more parts of the FDC.
Fixed dose combinations of four drugs (Isoniazid, Rifampicin, Pyrazinamide and Ethambutol), three drugs (Isoniazid, Rifampicin and Ethambutol) and two drugs (Isoniazid and Rifampicin) should be available.
Since it started to provide drug treatment the RNTCP has only provided treatment on three days a week. In 2014 the RNTCP recognised the need for daily dosing and announced a pilot in five states in December 2014. It was however very delayed.
Only three years later in 2017 the pilot was finally due to start. By this time most private sector physicians were providing their patients with a daily TB drug regimen. It was said that the delay in the rollout was “due to delays in procurement of the medicines needed for treatment”.
In February 2017 the Supreme Court directed that after a period of nine months, all new patients should be administered a daily regimen of TB drugs. A TB specialist Dr Raman Kakkar sought a change in the protocol for the treatment of TB. He had claimed that the current dosage practice was “unscientific” and “improper”. It promoted relapse and generated drug resistant strains in the patients. The relapsed cases were harder to treat than first time infections.
It was subsequently said by the RNTCP that:
“Under the new daily drug regimen, TB patients will be given fixed dose combinations (FDCs) – three or four drugs in specific dosages in a single pill – on a daily basis. The drugs will also be administered in a more scientific manner, according to the patient’s weight. The biggest advantage for the patient under the new regimen will be reduced pill burden, as instead of seven tablets, patients need consume only 2 or 3 tablets, according to their weight band” Senior RNTCP officials
However, as the drug regimen goes from three times a week to daily, more monitoring of patients may be required, as with the increased doses the patients may have more side effects.
In October 2017 the health minister Malladi Krishna Rao gave TB patients in Puducherry the first TB drugs to be taken by patients on a daily basis. 1“New drug regimen for TB patients”, the Hindu, October 27, 2017, www.thehindu.com/news/cities/puducherry/new-drug-regimen-for-tb-patients/ The quantity of the drugs to be taken will also depend on the patients weight. Each patient will receive through the RNTCP a month’s supply of drugs. The patients will be supervised taking the drugs using the DOTs strategy. The daily regimen will have to be followed by patients for six to eight months.
It is not clear however whether this is daily treatment for all TB patients or whether it is only for paediatric patients and patients with HIV TB co-infection.
With patients who have had treatment before, MDR-TB or R resistance must firstly be ruled out by a quality assured test.
Then if the TB patient is a previously treated patient as defined above, they should then receive the retreatment regime 2HREZS/1HREZ/5HRE containing first line drugs in a similar way to new TB patients. The main difference is the addition of streptomycin to the intensive phase.
It is not usual to add one TB drug to a failing regimen as this can encourage the development of resistance. But it may be considered that this is still sensible guidance as MDR-TB and rifampicin resistance will have already been excluded. So it is essential that this testing for additional resistance is done.
However, the effect on the patients could still be considerable. Streptomycin has to be painfully injected, and its common side effects include a loss of hearing.
Difficulties arise when testing for second line drugs is not available.
The TB drugs for RNTCP patients are supplied in an individual patient wise box which contains the entire course of treatment for the patient. In each patient wise box there are two pouches. One is for the intensive phase and the other is for the continuation phase.
The patient wise boxes are colour coded. Red boxes are for new patients, sometimes referred to as category 1. Blue boxes are for previously treated patients and are sometimes referred to as category 2. For paediatric TB patients separate patient wise boxes have been developed.
The response to therapy in patients with pulmonary TB, both new and retreatment patients, should be monitored. This should be done by follow-up sputum microscopy/culture (one specimen) at the time of completion of the intensive phase of treatment and at the end of treatment.
Would you like to send us a comment about this page?
(These are PDFs which may be slow to load & not all may be directly referred to on this page)
Guidelines on Programmatic Management of Drug-resistant Tuberculosis in India (PMDT) PMDT
Guidelines on Programmatic Management of Drug-resistant Tuberculosis in India Annexes (PMDT) PMDTAnnexures
RNTCP National Strategic Plan 2012 – 2017 NSP-2012-2017
RNTCP National Strategic Plan 2017 – 2025 NSP Draft 2017-2025
Standards for TB Care in India Standards TB Care India
TB India 2017 Revised National TB Control Programme Annual Status Report, New Delhi, 2017 TB India 2017
Technical and Operational Guidelines for Tuberculosis Control in India 2016 Part 1 TOG-Part-1
Technical and Operational Guidelines for Tuberculosis Control in India 2016 Part 2 TOG-Part-2
[ + ]
|1.||↑||“New drug regimen for TB patients”, the Hindu, October 27, 2017, www.thehindu.com/news/cities/puducherry/new-drug-regimen-for-tb-patients/|